



Pharmaceuticals —

Pipeline Overview and Progress

February 11, 2026 –
Investor Relations



Pharmaceuticals – Pipeline Overview¹ (as of February 11, 2026)

Phase I
VVD KEAP1 Act (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)  ●
225Ac-Pelgifatamab (BAY 3546828)  ●
225Ac-PSMA-Trillium (BAY 3563254)  ●
SOS1 Inhibitor (BAY 3498264)  ●
PRMT5 Inhibitor (BAY 3713372)  ●
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)  ●
225Ac-GPC3 (BAY 3547926)  ●
VVD WRN Inhibitor (VVD-214)  ●
KRAS G12D Inhibitor (BAY 3771249)  ●
Dual FIIa/Xa Inhibitor (BAY 3389934)  ●
GIRK4 Inhibitor (BAY 3670549) ●
BAY 3620122  ●
Multiple System Atrophy AAV Gene Therapy (AB-1005 aka <i>AAV2-GDNF-MSA</i>)  ●
Pompe Disease AAV Gene Therapy (AB-1009 aka <i>PROGRESS-GT LOPD</i>)  ●
LGMD2I/R9 AAV Gene Therapy (AB-1003 aka <i>LION-101</i>)  ●
GPR84 Antagonist (BAY 3178275)  ●
BAY 2701250  ●
Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)  ●
AT-05 SPECT Tracer  ●

Phase II
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)  ○
<i>// Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)</i>
Congestive Heart Failure AAV Gene Therapy (AB-1002)  ●
<i>// Congestive Heart Failure (GenePHIT)</i>
Inclocibart (anti-a2AP) (BAY 3018250)  ●
<i>// Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)</i>
Nurandociguat (sGC Activator Oral) (BAY 3283142)  ●
<i>// Chronic Kidney Disease (ALPINE-1)</i>
SEMA 3a Inhibitor (BAY 3401016)  ●
<i>// Alport Syndrome (ASSESS)</i>
Parkinson's Disease AAV Gene Therapy (AB-1005)  ●
<i>// Parkinson's Disease (REGENERATE-PD)</i>

Phase III
Darolutamide (AR Inhibitor)  ○
<i>// Adjuvant Prostate Cancer (DASL-HiCaP)</i>
<i>// Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)</i>
Sevabertinib (HER2/mEGFR Inhibitor)  ○
<i>// Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)</i>
Finerenone (MR Antagonist)  ○
<i>// Non-diabetic Chronic Kidney Disease (FIND-CKD)</i>
<i>// Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)</i>
Vericiguat (sGC Stimulator)  ○
<i>// Heart Failure (HFREF) (VICTOR²)</i>
Asundexian (FXIa Inhibitor)  ●
<i>// 2^o Stroke Prevention (OCEANIC-STROKE)</i>
Bemdaneprocel (Cell Therapy)  ●
<i>// Parkinson's Disease (exPDite-2)</i>
Mirena (Levonorgestrel-releasing Intrauterine System)  ○
<i>// Endometrial Hyperplasia (SUNFLOWER)</i>
124I-Evuzamitide (PET Tracer)  ●
<i>// Diagnosis of Cardiac Amyloidosis (REVEAL)</i>

Submissions
Sevabertinib (HER2/mEGFR Inhibitor)  ●
<i>// CN, JP: HER2-mut NSCLC 2L</i>
Finerenone (MR Antagonist)  ○
<i>// EU, CN: Heart Failure (HFmr/pEF)</i>
Aflibercept 8mg (VEGF-Inhibitor)  ○
<i>// JP, CN: Retinal Vein Occlusion</i>
Gadoquatrane (High Relaxivity Contrast Agent)  ●
<i>// US, EU, JP, CN: Magnetic Resonance Imaging</i>

- Oncology
- Cardiovascular / Renal
- Neurology & Rare Diseases
- Immunology
- Others

- New Molecular Entity
- Indication Expansion

 Protein Therapy
  Cell Therapy
  Genetic Therapy
  Radionuclide Therapy
  Imaging Agent
  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co



Pharmaceuticals – Pipeline Details Oncology¹

(as of February 11, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Adjuvant Prostate Cancer (DASL-HiCaP)					NCT04136353	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)					NCT05794906	Q3 2027	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)	Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)					NCT06452277	Q4 2027	Study ongoing
	Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)					NCT06760819	Q1 2027	Study ongoing
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Advanced Solid Tumors					NCT05954312	Q3 2030	Study ongoing
225Ac-Pelgifatamab (BAY 3546828)	Advanced Prostate Cancer					NCT06052306	Q2 2027	Study ongoing
225Ac-PSMA-Trillium (BAY 3563254)	Advanced Prostate Cancer					NCT06217822	Q2 2027	Study ongoing
SOS1 Inhibitor (BAY 3498264)	Advanced Solid Cancers					NCT06659341	Q3 2027	Study ongoing
PRMT5 Inhibitor (BAY 3713372)	MTAP-deleted Solid Tumors					NCT06914128	Q2 2029	Study ongoing
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)	Advanced Solid Tumors					NCT06804824	Q3 2027	Study ongoing
225Ac-GPC3 (BAY 3547926)	Advanced Liver Cancer					NCT06764316	Q3 2030	Study ongoing
VVD WRN Inhibitor (VVD-214)	Advanced Solid Tumors					NCT06004245	Q2 2027	Study ongoing
KRAS G12D Inhibitor (BAY 3771249)	Advanced Solid Tumors					NCT07207707	Q3 2026	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
 3 *Bayer acquired Noria and PSMA Therapeutics in 2021
 /// Bayer Pharmaceuticals /// Pipeline Overview February 11, 2026



Pharmaceuticals – Pipeline Details Cardiovascular / Renal¹

(as of February 11, 2026)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status	
Finerenone (MR Antagonist)	Non-diabetic CKD (<i>FIND-CKD</i>)						NCT05047263	Q1 2026	Study ongoing
	CKD in Type 1 Diabetes (<i>FINE-ONE</i>)		NCT05901831	Q3 2025	Study completed				
Vericiguat (sGC Stimulator)	Heart Failure (HFrEF) (<i>VICTOR²</i>)					NCT05093933	Q4 2024	Study completed	
Asundexian (FXIa Inhibitor)	2° Stroke Prevention (<i>OCEANIC-STROKE</i>)					NCT05686070	Q4 2025	Study completed	
Congestive Heart Failure AAV Gene Therapy (<i>AB-1002</i>)	Congestive Heart Failure (<i>GenePHIT</i>)					NCT05598333	Q4 2026	Study ongoing	
Inclisibart (anti-a2AP) (<i>BAY 3018250</i>)	Acute Ischemic Stroke; Pulmonary Embolism (<i>SIRIUS</i>)					NCT06149520	Q4 2025	Study completed	
Nurandociguat (sGC Act. Oral) (<i>BAY 3283142</i>)	Chronic Kidney Disease (CKD) (<i>ALPINE 1</i>)					NCT06522997	Q1 2026	Study ongoing	
SEMA 3a (<i>BAY 3401016</i>)	Alport Syndrome (<i>ASSESS</i>)					NCT07211685	Q3 2028	Study ongoing	
Dual FIIa/Xa Inhibitor (<i>BAY 3389934</i>)	Sepsis-Induced Coagulopathy					NCT06854640	Q1 2026	Study ongoing	
GIRK4 Inhibitor (<i>BAY 3670549</i>)	Atrial fibrillation	Undisclosed				n/a	Q4 2025	Study completed	
BAY 3620122	Vasoplegia					n/a	Q3 2026	Study ongoing	

Protein Therapy
 Cell Therapy
 Genetic Therapy
 Radionuclide Therapy
 Imaging Agent
 Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Conducted by Merck & Co



Pharmaceuticals – Pipeline Details Neurology / Rare Diseases¹

(as of February 11, 2026)


Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Bemdaneprocel (Parkinson's Disease Cell Therapy)	Parkinson's Disease (<i>exPDite-2</i>)					NCT06944522	Q1 2027	Study ongoing
Parkinson's Disease AAV Gene Therapy (<i>AB-1005</i>)	Parkinson's Disease (<i>REGENERATE-PD</i>)					NCT06285643	Q3 2028	Study ongoing
Multiple System Atrophy AAV Gene Therapy (<i>AB-1005 aka AAV2-GDNF-MSA</i>)	Multiple System Atrophy					NCT04680065	Q3 2026	Study ongoing
Pompe Disease AAV Gene Therapy (<i>AB-1009 aka PROGRESS-GT LOPD</i>)	Pompe Disease					NCT07282847	Q3 2028	Recruiting
LGMD2I/R9 AAV Gene Therapy (<i>AB-1003 aka LION-101</i>)	Limb-Girdle Muscular Dystrophy 2i					NCT05230459	Q4 2028	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



Pharmaceuticals – Pipeline Details Others¹

(as of February 11, 2026)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Mirena (Levonorgestrel-releasing Intrauterine System)	Endometrial Hyperplasia (<i>SUNFLOWER</i>)					NCT06904274	Q2 2027	Study ongoing
124I-Evuzamitide (PET Tracer)	Diagnosis of Cardiac Amyloidosis (<i>REVEAL</i>)					NCT06788535	Q1 2026	Study ongoing
GPR84 Antagonist (<i>BAY 3178275</i>)	Diabetic Neuropatic Pain					n/a	Q1 2024	Study completed
BAY 2701250	Pulmonary Hypertension					NCT06048120	Q2 2025	Study completed
Primary Photoreceptor Diseases Cell Therapy (<i>BRT-OpCT-001</i>)	Primary Photoreceptor Disease					NCT06789445	Q4 2029	Study ongoing
AT-05 SPECT Tracer	Diagnosis of Cardiac Amyloidosis					n/a	n/a	n/a

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit